Advanced breast cancer

A randomized study of different doses of epirubicin associated with fixed doses of cyclophosphamide and 5-fluorouracil

A. Riccardi, M. Giordano, S. Brugnatelli, G. Ucci, M. Danova, O. Mora, S. Fava, E. Ascari

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

A moderate increase in the dose of anthracycline could be feasible and of clinical benefit in advanced breast cancer. Between April 1991 and April 1994, 69 consecutive patients with recurrent or metastatic breast cancer were randomly treated with two regimens, including different dosages of epirubicin (75 versus 100 mg/m2) associated with the same dosage (600 mg/m2) of cyclophosphamide and 5-fluorouracil (75-FEC vs 100-FEC). Patients were planned to receive 6 courses at 21 day-intervals. Thirty-six patients received the 75-FEC regimen and 33 received the 100-FEC regimen. The two groups were comparable for age, menopausal status, disease-free interval, previous therapy, performance status and sites of disease. Over the whole study, the 100-FEC regimen has allowed a 18% actual increase in the epirubicin dosage over the 75-FEC regimen. Overall response rate was 56% for the 100-FEC and 51% for the 75-FEC, with the 100-FEC inducing some more complete responses than the 75-FEC (38% vs 23%). Survival (but not time to progression) tended to be longer with the 100- than with the 75-FEC (median: 20 vs 13 mos, p

Original languageEnglish
Pages (from-to)577-582
Number of pages6
JournalOncology Reports
Volume2
Issue number4
Publication statusPublished - 1995

Fingerprint

Epirubicin
Fluorouracil
Cyclophosphamide
Breast Neoplasms
Anthracyclines
Survival
Therapeutics

Keywords

  • Advanced breast cancer
  • Clinical benefit
  • Drug dosage
  • Epirubicin
  • Tolerability

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Advanced breast cancer : A randomized study of different doses of epirubicin associated with fixed doses of cyclophosphamide and 5-fluorouracil. / Riccardi, A.; Giordano, M.; Brugnatelli, S.; Ucci, G.; Danova, M.; Mora, O.; Fava, S.; Ascari, E.

In: Oncology Reports, Vol. 2, No. 4, 1995, p. 577-582.

Research output: Contribution to journalArticle

@article{42e2e87718ba43afb3920fbac7df00ed,
title = "Advanced breast cancer: A randomized study of different doses of epirubicin associated with fixed doses of cyclophosphamide and 5-fluorouracil",
abstract = "A moderate increase in the dose of anthracycline could be feasible and of clinical benefit in advanced breast cancer. Between April 1991 and April 1994, 69 consecutive patients with recurrent or metastatic breast cancer were randomly treated with two regimens, including different dosages of epirubicin (75 versus 100 mg/m2) associated with the same dosage (600 mg/m2) of cyclophosphamide and 5-fluorouracil (75-FEC vs 100-FEC). Patients were planned to receive 6 courses at 21 day-intervals. Thirty-six patients received the 75-FEC regimen and 33 received the 100-FEC regimen. The two groups were comparable for age, menopausal status, disease-free interval, previous therapy, performance status and sites of disease. Over the whole study, the 100-FEC regimen has allowed a 18{\%} actual increase in the epirubicin dosage over the 75-FEC regimen. Overall response rate was 56{\%} for the 100-FEC and 51{\%} for the 75-FEC, with the 100-FEC inducing some more complete responses than the 75-FEC (38{\%} vs 23{\%}). Survival (but not time to progression) tended to be longer with the 100- than with the 75-FEC (median: 20 vs 13 mos, p",
keywords = "Advanced breast cancer, Clinical benefit, Drug dosage, Epirubicin, Tolerability",
author = "A. Riccardi and M. Giordano and S. Brugnatelli and G. Ucci and M. Danova and O. Mora and S. Fava and E. Ascari",
year = "1995",
language = "English",
volume = "2",
pages = "577--582",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Advanced breast cancer

T2 - A randomized study of different doses of epirubicin associated with fixed doses of cyclophosphamide and 5-fluorouracil

AU - Riccardi, A.

AU - Giordano, M.

AU - Brugnatelli, S.

AU - Ucci, G.

AU - Danova, M.

AU - Mora, O.

AU - Fava, S.

AU - Ascari, E.

PY - 1995

Y1 - 1995

N2 - A moderate increase in the dose of anthracycline could be feasible and of clinical benefit in advanced breast cancer. Between April 1991 and April 1994, 69 consecutive patients with recurrent or metastatic breast cancer were randomly treated with two regimens, including different dosages of epirubicin (75 versus 100 mg/m2) associated with the same dosage (600 mg/m2) of cyclophosphamide and 5-fluorouracil (75-FEC vs 100-FEC). Patients were planned to receive 6 courses at 21 day-intervals. Thirty-six patients received the 75-FEC regimen and 33 received the 100-FEC regimen. The two groups were comparable for age, menopausal status, disease-free interval, previous therapy, performance status and sites of disease. Over the whole study, the 100-FEC regimen has allowed a 18% actual increase in the epirubicin dosage over the 75-FEC regimen. Overall response rate was 56% for the 100-FEC and 51% for the 75-FEC, with the 100-FEC inducing some more complete responses than the 75-FEC (38% vs 23%). Survival (but not time to progression) tended to be longer with the 100- than with the 75-FEC (median: 20 vs 13 mos, p

AB - A moderate increase in the dose of anthracycline could be feasible and of clinical benefit in advanced breast cancer. Between April 1991 and April 1994, 69 consecutive patients with recurrent or metastatic breast cancer were randomly treated with two regimens, including different dosages of epirubicin (75 versus 100 mg/m2) associated with the same dosage (600 mg/m2) of cyclophosphamide and 5-fluorouracil (75-FEC vs 100-FEC). Patients were planned to receive 6 courses at 21 day-intervals. Thirty-six patients received the 75-FEC regimen and 33 received the 100-FEC regimen. The two groups were comparable for age, menopausal status, disease-free interval, previous therapy, performance status and sites of disease. Over the whole study, the 100-FEC regimen has allowed a 18% actual increase in the epirubicin dosage over the 75-FEC regimen. Overall response rate was 56% for the 100-FEC and 51% for the 75-FEC, with the 100-FEC inducing some more complete responses than the 75-FEC (38% vs 23%). Survival (but not time to progression) tended to be longer with the 100- than with the 75-FEC (median: 20 vs 13 mos, p

KW - Advanced breast cancer

KW - Clinical benefit

KW - Drug dosage

KW - Epirubicin

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=0029009639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029009639&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 577

EP - 582

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -